Company Update - Q1 2026 Unaudited Results (30-Apr-2026)

Apr 2026

PT Kalbe Farma Tbk (KLBF IJ/KLBF.JK)

Company Update Q126

1 1

YTD Mar 2026

• Key Updates 04
• Business Strategies 09
• Financial Overview 24
• Appendix 1 30
• Appendix 2 36

3

4

Key updates

Business Strategy

Financial Updates

Appendix I

Appendix II

‌More than Half a Century of Providing Wide-Range Healthcare Solutions

Corporate Overview

Establishment

1966

IDX Listed

1991

7%

International

36.0%

Distribution &

Logistics

22.3%

Nutritionals

93%

Domestic

Prescription Pharmaceuticals

Net Sales 27.2%

IDR 9.7 tn

14.5%

Consumer Health

Market Capitalization

IDR 46.11 tn | USD 2.71 bn

Free Float*

38.31%

Treasury Shares

3.34%

As of 31 Mar'26

*Free FloaT is calculaTed as ToTal shares deducTed by The majoriTy, boards, Treasury, and scripT shares

Key updates

Business Strategy

Financial Updates

Appendix I

Appendix II

Solid Fundamentals for Future Growth

Key Takeaways

10.1% -4.4%

net sales growth net profit growth

Key Updates

Positive organic top-line growth

driven by volume Marketing investment to sustain growth

Progressing on track in key projects to drive future growth

Key Challenges

Pressure on purchasing power in domestic market Exchange rate fluctuation amidst geopolitics and trade war

Mitigation

Securing raw material availability Diversifying import currency

Strategic Partnerships and Investments

• Strengthening product portfolio

  through collaboration

• Established JV Livzon Pharma Indonesia to manufacture pharmaceuticals ingredients

• Radiopharmaceuticals facilities

  (cyclotron)

• Biologic products' commercialization

• Strategic Partnership with Alliance Pharma Co.,Ltd. to penetrate the Thai market

• Moving towards local manufacturing of medical equipment

Driving Growth and Improving Healthcare Resilience through Innovation

2026 Key Strategies

Investing for long term growth through innovation and collaboration

Distribution & Logistics

• Deepening penetration in selected countries

• Optimizing Alliance Pharma to bring biologics

product to Thai market

• New potential principals

• Strengthening medical and distribution channel

• Providing more value added services

• Rejuvenating our brands to drive competitive advantage

• Expanding into preventive and non-curative

• Strengthening nutritionals presence in liquid and lifestyle categories

Key updates

Business Strategy

Financial Updates

Appendix I

Appendix II

Rejuvenating Our Strong Brands

to Win the Market

8

9

Building Specialty Portfolio

Growing specialty category by commercialization and expansion of innovative portfolio, supported by local manufacturing

Participation in National Health Insurance

Providing affordable, quality medicines through E-Catalog

Enhance Business Growth

by leveraging on strong commercial team and distribution network

Strategic Collaborations to Accelerate Growth

Prescription Pharmaceuticals

Global Starway Synergy

Dec 2022

Securing raw materials and

managing currency risk

Kalventis

Dec 2022

Expanding portfolio in prescription pharma

Alliance Pharma

May 2024

Expanding distribution in Thailand

Livzon Pharma Indonesia

July 2024

Pharmaceutical ingredients manufacturing

Oncology

Biological-based

Others

Manufacturing Facilities

Innovative Specialty Products

Key updates

Business Strategy

Financial Updates

Appendix I

Appendix II

Prescription Pharmaceuticals

Specialty Portfolio

Serplulimab

Biologics

Efepoetin Alfa

Zerpidio

• Approval in Dec 2023

Efesa

• Approval for non-dialysis indication in October 2023

• On progress to focus on • Commercialization in 2024 commercialization in Indonesia • Clinical trial application approved in EMA

  • Approved and launched in Cambodia

  • Leading in the Long-Acting EPO in Indonesia

Biosimilar

Erythropoietin

(Hemapo)

Insulin

(Ezelin)

GCSF Rituximab

(Leucogen) (Rituxikal)

Trastuzumab

(Herzemab)*

Bevacizumab

(Avamab)*

*On progress to locally manufactured

Oncology

Cell-therapy

Insulin

Vaccines

Sustaining Growth Through Our Complete Portfolio

Prescription Pharmaceuticals

8.5% 47.3%

net sales growth gross profit margin

from Rp2,424 bn to 2,630 bn from 49.8% due to raw materials

and product mix

Contribution to total net sales

27.2%

Licensed

27% 27%

46%

Unbranded generics

Kalbe

14%

a

10%

others

58%

Market Share

b

6%

c 5%

d

e 4%

3%

Branded

generics

*IQVIA 4Q 25

Expanding Customer Base

Leveraging solid customer base in OTC and health supplement with brand rejuvenation, branding and positioning

Driving Product Innovation

Expanding to preventive categories as future growth driver

Expanding into Preventive and Non-Curative Category

Driving product innovation and new product launches in

potential categories

new

new

Extra Joss

Ultimate

Promag Herbal

Mixagrip Herbal Greges

BEJO Jahe Merah

new

Fatigon Spirit

(Stamina)

Sakatonik Curcuma Madu

Cerebrofort Gummy

Komix Herbal Sakatonik

Activ Gummy

Femmy Fyber

~30-70% market share in relevant categories

Source: IQVIA 4Q24

Extra Joss

(Energy Drink)

Promag

(Antacids)

Entrostop

(Anti Diarrhea)

Mixagrip

Komix

Woods

Procold

(Cough & Cold)

Consumer Health

Driving Growth Through Brand Rejuvenation

Consumer Health

3.2% 64.6%

net sales growth gross profit margin

from Rp1,360 bn to 1,403 bn from 66.0% due to product mix and

raw material price

Contribution to total net sales

14.5%

Health

Supplements

28%

Kalbe 10%

a 6%

b 5%

Market

Share

c 4%

d 4%

e 3%

Others 68%

OTC

72%

*IQVIA 4Q 25

Solid Product Portfolio

Compelling portfolio consisting of functional nutritional and healthy lifestyle products

Strengthening Brand Equity

Investing to strengthen brand equity and communication

Complete Portfolio for Future Expansion

Nutritionals

Expecting Mothers

Senior & Clinical

Lactating Mothers

Adults

Complete product offering for all life stages with strong functionality

Kids

Teens

Navigating Market Challenges

Nutritionals

1.6% 53.0%

net sales growth gross profit margin

from Rp2,127 bn to 2,160 bn from 54.2% due to raw material price

and product mix

f

3%

others

8%

Kalbe

16%

e

7%

d

4% Market Share

c 15%

a

27%

b

19%

Contribution to total net sales

22.3%

Specialty

15%

Adults

27%

58%

Kids

*Nielsen 4Q 25

Access to healthcare

Strong Distribution Infrastructure

Expansive multi-channels network with coverage in 72

branches

Leveraging digitalization

Through EMOS and MOSTRANS B2B transportation

solutions

Optimizing Distribution Network

Optimized medical and distribution channel through operational excellence